Ms. Moore has partnered with Lumenis as a brand ambassador for OptiLight to tell her story and empower others.
After suffering for years with dry, itchy, burning eyes, Ms. Moore learned her problem was dry eye disease—a condition that affects millions of people. After undergoing treatment with OptiLight, Ms. Moore’s quality of life greatly improved.
OptiLight is a revolutionary, patented treatment that is the first and only light-based therapy for dry eye disease.
Dr. Mei Fleming ensures her patients “See better than 20/20 in style” and get comprehensive dry eye disease management, including OptiLight from Lumenis.
Dr. Laura M. Periman explains the multifactorial complexity of dry eye disease—and how OptiLight is helping the future look bright.
Jennifer Tsai, OD, has a tech-forward practice—the first to offer the easy-to-use, rapid-ROI OptiLight for effective management of dry eye disease.
Eyes on Eyecare gathers insights from patients and practitioners on the first and only FDA-approved IPL for dry eye management: OptiLight by Lumenis.
As an early adopter, Art Epstein, OD explains his first impressions of the new OptiLight and why he feels it’s a difference-maker for doctors and dry eye patients alike.
Patented Lumenis Optimal Pulse Technology (OPT) becomes the first IPL approved for management of dry eye disease due to MGD, and Lumenis launches OptiLight.
In a prospective, multicenter, randomized control trial, Lumenis IPL with OPT™ combined with MGX significantly improved signs and symptoms of DED due to MGD.
Presenting OptiLight, Lumenis revolutionary new light- based treatment for dry eye disease. Dr. Adler hosts Drs. Toyos, Periman and Epstein, plus OptiLight patients
In a prospective paired-eye study of patients wearing contact lenses and experiencing contact lens related dry eye, eyes treated with Lumenis IPL with OPTTM improved in signs and symptoms of dry eye disease (DED).